OMER Omeros
- 3.040
- -0.050-1.62%
Omeros News
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Omeros (OMER) and Urogen Pharma (URGN)
Omeros Analyst Ratings
Omeros' Clinical Trials Setbacks and Financial Standing Lead to Underperform Rating: An Analysis
UBS Adjusts Omeros Price Target to $4 From $2, Maintains Neutral Rating
Bank of America Securities Keeps Their Sell Rating on Omeros (OMER)
Analysts Offer Insights on Healthcare Companies: Omeros (OMER) and SAGE Therapeutics (SAGE)
Needham Reaffirms Their Hold Rating on Omeros (OMER)
Omeros Analyst Ratings
UBS Downgrades Omeros to Neutral, Lowers Price Target to $2
Needham Reaffirms Their Hold Rating on Omeros (OMER)
BofA Securities Downgrades Omeros to Underperform Rating From Neutral, Price Target Is $3
Omeros Analyst Ratings
B of A Securities Downgrades Omeros to Underperform, Announces $3 Price Target
Omeros Downgraded at Bank of America After FDA Snub for Narsoplimab Appeal
Maxim Group Keeps Their Hold Rating on Omeros (OMER)
Analysts Offer Insights on Healthcare Companies: Omeros (OMER), Atossa Therapeutics (ATOS) and PDS Biotechnology (PDSB)
BofA Securities Downgrades Omeros to Neutral From Buy, Sets $4 Price Target
Omeros Cut to Neutral From Buy by B of A Securities
Omeros Price Target Cut to $4.00/Share From $12.00 by B of A Securities
Omeros analyst ratings
Analysis
Price Target
No Data
